Scorpius Holdings, Inc., a pharmaceutical company, announced on Monday a significant amendment to its financial and acquisition agreements with Elusys Holdings Inc. The Delaware-incorporated firm, previously known as NightHawk Biosciences and Heat Biologics (OTC:SCPXD), disclosed the update in a recent SEC filing.
Under the new terms, Scorpius Holdings entered into a Note Cancellation and Amendment to Asset and Equity Interests Purchase Agreement, effectively canceling a $750,000 promissory note issued to Elusys Holdings on May 1, 2024. This non-convertible note, bearing a 1% interest rate, was part of an earlier arrangement dated December 11, 2023.
The amendment not only nullifies the note but also revises the Asset and Equity Interests Purchase Agreement. The original agreement required Elusys Holdings to pay royalty fees to Scorpius Holdings. With the amendment, these royalty payments are replaced by a lump-sum cash payment of $2.5 million due on or before December 31, 2028.
The financial reshuffle signifies a strategic move by Scorpius Holdings, based in Morrisville, North Carolina, as it continues to navigate the pharmaceutical preparations sector. The company's stock is listed on the NYSE American LLC under the ticker SCPX.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.